From: Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
 | Hazard Ratio | 95.0% CI | P value | |
---|---|---|---|---|
Lower | Upper | Â | ||
SGLT-2 (yes/no) | 0.300 | 0.104 | 0.865 | 0.026 |
Age | 1.016 | 0.983 | 1.050 | 0.338 |
Gender | 0.494 | 0.241 | 1.014 | 0.054 |
Cancer Types | Â | Â | Â | 0.030 |
 NSCLC | 0.583 | 0.214 | 1.588 | 0.291 |
 Melanoma | 0.401 | 0.165 | 0.979 | 0.045 |
 Renal Cell Carcinoma | 2.716 | 1.024 | 7.202 | 0.045 |
 Hepatocellular Carcinoma | 3.515 | 0.617 | 20.044 | 0.157 |
 Breast | 1.092 | 0.264 | 4.520 | 0.903 |
 Cervical Squamous | 1.180 | 0.355 | 3.925 | 0.787 |
Chemotherapy/Biological_plus_ICIs | Â | Â | Â | 0.115 |
 Chemo_plus_ICIs | 0.770 | 0.301 | 1.967 | 0.584 |
 Biological_plus_ICIs | 0.247 | 0.066 | 0.923 | 0.038 |
Cancer Stage | Â | Â | Â | 0.175 |
 Stage at immuno Start(1) | 0.450 | 0.031 | 6.517 | 0.559 |
 Stage at immuno Start(2) | 1.565 | 0.152 | 16.118 | 0.706 |
Hypertension | 1.112 | 0.543 | 2.275 | 0.772 |
Ischemic Heart Disease-Baseline | 0.713 | 0.308 | 1.648 | 0.429 |
Obesity | 1.717 | 0.407 | 7.238 | 0.461 |
Hyperlipidemia | 0.537 | 0.257 | 1.122 | 0.098 |
Chronic Kidney Disease | .768 | .244 | 2.423 | 0.653 |
Statin | 1.720 | .814 | 3.634 | 0.155 |
RAASi treatment | .898 | .445 | 1.813 | 0.765 |